Information Provided By: 
Fly News Breaks for March 13, 2017
ACOR
Mar 13, 2017 | 06:37 EDT
Janney Capital analyst Ken Trbovich upgraded Acorda Therapeutics to Buy and raised his fair value estimate for the shares to $38 from $23. The stock closed Friday down $2.00 to $28.15. The positive decision from the Patent Trial Appeal Board regarding the inter-partes review of four of its patents protecting Ampyra is a "significant victory" for Acorda, Trbovich tells investors in a research note. The analyst now has greater confidence that Acorda will prevail in the pending patent litigation with generic filers in the U.S. District Court.
News For ACOR From the Last 2 Days
There are no results for your query ACOR
